UBS initiated coverage of Addus HomeCare (ADUS) with a Buy rating and $145 price target The company is positioned to benefit from an aging population with increased co-morbities and a continued shift to low-cost site of care settings, the analyst tells investors in a research note. The firm believes Addus’ current valuation provides investors a buying opportunity with the stock discounted as a result of ongoing noise related to Medicaid cuts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Buy Rating for Addus Homecare: Attractive Valuation and Strong Growth Prospects Amidst Legislative Changes
- Addus HomeCare files automatic mixed securities shelf
- Addus HomeCare price target raised to $109 from $83 at Barclays
- Addus Homecare Appoints New President and COO
- Addus HomeCare selloff on COO hire overdone, says TD Cowen